Renalytix to Present at Cowen 42nd Annual Health Care Conference
Renalytix plc (NASDAQ: RNLX) announced their participation in the Cowen 42nd Annual Health Care Conference, set for March 9, 2022, at 10:30 a.m. EST.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Renalytix plc (NASDAQ: RNLX) announced their participation in the Cowen 42nd Annual Health Care Conference, set for March 9, 2022, at 10:30 a.m. EST. The event will feature a fireside chat with the company's management and will be accessible via a live and archived webcast on their investors' website. Renalytix specializes in bioprognosis for kidney health, with their leading product, KidneyIntelX, receiving Breakthrough Designation from the U.S. FDA to enhance diagnosis and management of kidney disease.
Details
News Market Reaction – RNLX
The recorded move for RNLX in the trading session of this news was -1.00%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK and SALT LAKE CITY, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (“Renalytix” or the “Company”) today announced the Company will be presenting at the upcoming virtual Cowen 42nd Annual Health Care Conference.
Renalytix’s management is scheduled to participate in a fireside chat on Wednesday, March 9, 2022, at 10:30 a.m. EST. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at investors.renalytix.com. The company will also be available for virtual 1X1 meetings with investors registered for the event.
About Renalytix
Renalytix (NASDAQ: RNLX) (LSE: RENX) is the global founder and leader in the new field of bioprognosis™ for kidney health. The company has engineered a new solution that successfully enables early-stage CKD progression risk assessment. The Company’s lead product, KidneyIntelX, has been granted Breakthrough Designation by the U.S. Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com). For more information, visit www.renalytix.com.
For further information, please contact:
| Renalytix plc | www.renalytix.com | ||
| James McCullough, CEO | Via Walbrook PR | ||
| Stifel (Nominated Adviser, Joint Broker) | Tel: 020 7710 7600 | ||
| Alex Price / Nicholas Moore | |||
| Investec Bank plc (Joint Broker) | Tel: 020 7597 4000 | ||
| Gary Clarence / Daniel Adams | |||
| Walbrook PR Limited | Tel: 020 7933 8780 or renalytix@walbrookpr.com | ||
| Paul McManus / Lianne Applegarth | Mob: 07980 541 893 / 07584 391 303 | ||
| CapComm Partners | |||
| Peter DeNardo | Tel: 415-389-6400 or investors@renalytix.com | ||
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.